Acid Blue 25

Acid Blue 25

SCHEMBL790822

Nc1c(S(=O)(=O)[O-])cc(Nc2ccccc2)c2c1C(=O)c1ccccc1C2=O.[Na+]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acid Blue 25. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
P2RY4 known ✓ P51582 13/20 1.00
P2RY12 known ✓ Q9H244 9/20 1.00
P2RY2 known ✓ P41231 7/20 1.00
P2RY6 known ✓ Q15077 4/20 1.00
P2RY1 known ✓ P47900 2/20 1.00
CDK2 P24941 2/20 1.00
MET P08581 3/20 0.86
HGF P14210 2/20 0.86
ENTPD1 P49961 2/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acid Blue 25 SCHEMBL29355038 1.00 P2RY4 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL29395314 0.93 P2RY12 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL3019529 0.93 P2RY12 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL30504038 0.93 P2RY12 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL3029895 0.92 MET (0.93) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL3026030 0.92 P2RY12 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL791055 0.91 P2RY4 (0.82) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL3030129 0.90 P2RY4 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL3020870 0.90 P2RY4 (0.82) P2RY4P2RY12P2RY2P2RY6CDK2
SCHEMBL3021097 0.90 P2RY4 (1.00) P2RY4P2RY12P2RY2P2RY6CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616449-A1 ANTHRAQUINONE COMPOUNDS AND THEIR USES Dundalk Institute of Technology (IE) 2013-07-24 EP claimed
WO-2012035122-A1 ANTHRAQUINONE COMPOUNDS AND THEIR USES DUNDALK INSTITUTE OF TECHNOLOGY (IE) 2012-03-22 WO claimed
JP-4750804-B2 2011-08-17 JP claimed
US-20080306026-A1 Capsule Formulation SYNGENTA CROP PROTECTION LLC 2008-12-11 US claimed
JP-2008531514-A 2008-08-14 JP claimed
EP-1850664-A2 PESTICIDAL CAPSULE FORMULATION Syngeta Participations AG (CH) 2007-11-07 EP claimed
WO-2006089747-A2 PRESTICIDAL CAPSULE FORMULATION SYNGENTA PARTICIPATIONS AG (CH) 2006-08-31 WO claimed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP claimed
EP-4426280-B1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS GURBA ALEXANDRE (CH) 2026-03-18 EP disclosed
US-12319037-B2 Transparent polymer film with discoloration compensation KLÖCKNER PENTAPLAST GMBH (DE) 2025-06-03 US disclosed
US-20250057791-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS GURBA ALEXANDRE (CH) 2025-02-20 US disclosed
US-20240083151-A1 TRANSPARENT POLYMER FILM WITH DISCOLORATION COMPENSATION KLÖCKNER PENTAPLAST GMBH (DE) 2024-03-14 US disclosed
US-11858241-B2 Transparent polymer film with discolouration compensation KLÖCKNER PENTAPLAST GMBH (DE) 2024-01-02 US disclosed
WO-2023111938-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS GURBA, Alexandre (CH) 2023-06-22 WO disclosed
EP-1002021-A1 DISPERSING AGENTS AND DISPERSIONS MADE THEREFROM ICI AMERICAS INC. (US) 2000-05-24 EP disclosed
WO-1999005225-A1 DISPERSING AGENTS AND DISPERSIONS MADE THEREFROM ICI AMERICAS INC. (US) 1999-02-04 WO disclosed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP disclosed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP disclosed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO disclosed
US-4289496-A LOW LIQUID TO MATERIAL RATIO RESULTING IN UNIFORMITY OF FINISHING SANDOZ LTD. (CH) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057791-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS P2RX2, P2RX3, P2RX1 P2RY4 12/4885P2RY12 16/4885P2RY2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.